Marex Group’s Applied Therapeutics APLT Stock Holding History

Marex Group’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,000	Closed	-$128K	–	686
2024 Q3	$128K	Hold	15,000	–	–	﹤0.01%	522
2024 Q2	$70K	Buy	+15,000	New	+$71K	﹤0.01%	582

Other funds holding APLT

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Marex Group's APLT Position: Q4 2024 in Review

Marex Group sold out of Applied Therapeutics (APLT) in Q4 2024, closing a stake of 15,000 shares — an estimated $128K sold.

Marex Group first reported a position in APLT in Q2 2024 and held it in 2 quarters. The position peaked at $128K in Q3 2024. 118 funds tracked by Wall St. Rank hold APLT as of Q4 2024.

Marex Group reported no remaining Applied Therapeutics position as of Q4 2024 after selling out during the quarter.
Marex Group sold 15,000 Applied Therapeutics shares in Q4 2024, an estimated $128K.
Marex Group first reported a position in Applied Therapeutics in Q2 2024 and held it in 2 quarters.
Marex Group's Applied Therapeutics position peaked at $128K in Q3 2024.
118 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2024.

Based on Marex Group's 13F filing for Q4 2024, filed 2 Apr 2026.